This week’s International Cannabis Business Conference (ICBC) in Berlin once again proved to be an inspiring forum for fostering open discussion and international collaboration within the cannabis sector.
Representing Curaleaf International, Torst en Greif of Four 20 Pharma GmbH joined the ‘Medical Cannabis in Germany’ panel alongside other leading voices in the sector.
Germany continues to hold a significant position as a key player in charting the future trajectory of medical cannabis across Europe. As such, the panel addressed critical topics including the evolving regulatory landscape and supply chains, and the paramount issue of patient access within the German market. The event was notably well-attended, with attendees from across the globe, underscoring the strong interest and engagement in the advancements within this dynamic sector.
Events like the ICBC in Berlin provide invaluable opportunities to share insights, forge partnerships, and collectively work towards a more accessible and well-regulated future for medical cannabis.
